Marpai, Inc. — Cyborg Score 4/10

Strategic Profile

Marpai operates in the $22 billion TPA market, targeting self-funded health plans representing over $1 trillion in annual healthcare claims. The company's competitive advantage stems from its integrated suite of services—including clinical care management, pharmacy benefits administration, repricing insights, and ancillary services—combined with its proprietary deep learning algorithms for member health prediction and cost containment.

Cyborg Score Rationale

Marpai operates in an attractive market with strong demand for cost-containment solutions, but the company faces operational challenges reflected in recent losses exceeding expectations (Q3 2025 EPS of -$0.20). The business model is sound, but execution and profitability remain uncertain.

Top Insights

• Addresses $22B TPA market with proprietary AI-driven healthcare management platforms
• Integrated service offering (TPA + PBM + clinical management) provides sticky customer relationships and multiple revenue streams
• Recent significant losses and lower-than-expected Q3 2025 earnings suggest scaling challenges
• Strong insider buying activity and recent capital raises indicate management confidence, but stock has faced severe headwinds

Named Competitors

• Optum — Largest TPA and healthcare benefits operator
• Caremark — Dominant pharmacy benefit manager
• Molina Healthcare — Managed care and TPA services
• Oscar Health — Technology-driven health plan operator

Recent Developments

• (Q3 2025) Larger-than-expected loss with EPS of -$0.20
• (Recent) Renewed agreement to access Aetna Signature Administrator PPO network
• (Recent) Appointment of Mimi Davis as President of MarpaiRx pharmacy benefit management division
• (Recent) $200,000 investment from HillCour Investment Fund

Open the full interactive Marpai, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.